Human Reproduction, Vol. 17, No. 9, 2219-2227,
September 2002
© 2002 European Society of Human Reproduction and Embryology
What is polycystic ovary syndrome?
Are national views important?*
1 Department of Reproductive Medicine, The General Infirmary, Leeds, LS2 9NS and 2 Division of Public Health and Primary Health Care, University of Oxford, UK
Polycystic ovary syndrome (PCOS) is a true syndrome, being a heterogeneous collection of signs and symptoms that gathered together form a spectrum of a disorder with a mild presentation in some, whilst in others there is a severe disturbance of reproductive, endocrine and metabolic function. There has been much debate about phenotype and, more recently, genotype. There has also been scepticism in some quarters, with a feeling that we may be looking at one end of a spectrum that is in reality `normal', or perhaps a consequence of the modern disease of obesity. Whilst the polycystic ovary is at the centre of the syndrome, it is external effects such as hyperinsulinism, that influence its expression. There is no consensus on the definition of PCOS and so studies that compare epidemiology and treatments often have very different starting points, and so cannot be compared. In this debate we wish to re-explore our current thinking on PCOS, with a particular emphasis on the British and European perspective and invite others to contribute to the discussion which could form the basis for an international consensus.
Key words: hyperandrogenism/hyperinsulinaemia/ovarian ultrasound/polycystic ovaries/polycystic ovary syndrome
* This paper was presented at The Serono Symposium on Polycystic Ovary Syndrome, IFFS, Melbourne, 24th November 2001
3 To whom correspondence should be addressed. E-mail: adam.balen{at}leedsth.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. E. Lujan, T. G. Bloski, D. R. Chizen, D. C. Lehotay, and R. A. Pierson Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome Hum. Reprod., October 24, 2009; (2009) dep363v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hudecova, J. Holte, M. Olovsson, and I. Sundstrom Poromaa Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve Hum. Reprod., May 1, 2009; 24(5): 1176 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.L. Jones, J.M. Hall, A.H. Balen, and W.L. Ledger Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review Hum. Reprod. Update, January 1, 2008; 14(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H Balen and A. J Rutherford Managing anovulatory infertility and polycystic ovary syndrome BMJ, September 29, 2007; 335(7621): 663 - 666. [Full Text] [PDF]
|
|
|
|
|
|
L. Barnard, D. Ferriday, N. Guenther, B. Strauss, A.H. Balen, and L. Dye Quality of life and psychological well being in polycystic ovary syndrome Hum. Reprod., August 1, 2007; 22(8): 2279 - 2286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Costello, B. Shrestha, J. Eden, N. P. Johnson, and P. Sjoblom Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review Hum. Reprod., May 1, 2007; 22(5): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H. F. Escobar-Morreale, W. Futterweit, O. E. Janssen, R. S. Legro, R. J. Norman, A. E. Taylor, et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4237 - 4245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tang, J. Glanville, N. Orsi, J. H. Barth, and A. H. Balen The use of metformin for women with PCOS undergoing IVF treatment Hum. Reprod., June 1, 2006; 21(6): 1416 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Handelsman The Rationale for Banning Human Chorionic Gonadotropin and Estrogen Blockers in Sport J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1646 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lo, S. L. Feigenbaum, J. Yang, A. R. Pressman, J. V. Selby, and A. S. Go Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1357 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H Balen, M. Dresner, E. M Scott, and J. O Drife Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ, February 25, 2006; 332(7539): 434 - 435. [Full Text] [PDF]
|
|
|
|
|
|
T. Tang, J. Glanville, C. J. Hayden, D. White, J. H. Barth, and A. H. Balen Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study Hum. Reprod., January 1, 2006; 21(1): 80 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Wely, N. Bayram, P.M.M. Bossuyt, and F. van der Veen Laparoscopic electrocautery of the ovaries versus recombinant FSH in clomiphene citrate-resistant polycystic ovary syndrome. Impact on women's health-related quality of life Hum. Reprod., October 1, 2004; 19(10): 2244 - 2250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Nikolaou and C. Gilling-Smith Early ovarian ageing: are women with polycystic ovaries protected? Hum. Reprod., October 1, 2004; 19(10): 2175 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schmid, S. Kirchengast, E. Vytiska-Binstorfer, and J. Huber Infertility caused by PCOS--health-related quality of life among Austrian and Moslem immigrant women in Austria Hum. Reprod., October 1, 2004; 19(10): 2251 - 2257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Wely, N. Bayram, F. van der Veen, and P.M.M. Bossuyt An economic comparison of a laparoscopic electrocautery strategy and ovulation induction with recombinant FSH in women with clomiphene citrate-resistant polycystic ovary syndrome Hum. Reprod., August 1, 2004; 19(8): 1741 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Legro, E. Myers, and for the Reproductive Medicine Network Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome? Hum. Reprod., August 1, 2004; 19(8): 1697 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Taponen, S. Ahonkallio, H. Martikainen, R. Koivunen, A. Ruokonen, U. Sovio, A-L. Hartikainen, A. Pouta, J. Laitinen, V. King, et al. Prevalence of polycystic ovaries in women with self-reported symptoms of oligomenorrhoea and/or hirsutism: Northern Finland Birth Cohort 1966 Study Hum. Reprod., May 1, 2004; 19(5): 1083 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bayram, M. van Wely, E. M Kaaijk, P. M M Bossuyt, and F. van der Veen Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial BMJ, January 24, 2004; 328(7433): 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Orvieto and Z. Ben-Rafael Polycystic ovary syndrome: a simplified approach based on the evolving set of symptoms Hum. Reprod., April 1, 2003; 18(4): 896 - 897. [Full Text] [PDF]
|
|